Two ruthenium (III) Our results show that especially the transferrin-bound forms exhibit high antiproliferative activity, which exceeds that of the free complex, indicating that this protein can act as a carrier ofthe ruthenium complexes into the tumor cell.
Introduction
A number of Ru(III) complexes exhibit antitumour activity in animal models (Clarke, 1989 . Furthermore, both complexes exhibit antiproliferative activity in two human colon cancer cell lines (SW707 and SW948) (Galeano et al., 1992 (Clarke, 1989) . Indeed, it has been previously reported that transferrin is responsible for the selective delivery of radioactive 67Ga(III) complexes to tumor tissues (Ward and Taylor, 1988) . The simaificance of cellular uptake of transferrin with respect to various malignant diseases has been reviewed (Aulbert, 1986 (Kratz et al., 1992 and 1993) and especially with apotransferrin (Kratz et al., 1994a) In order to prepare 11.0 ml of the protein/complex solution with 2 equivalents of the complex, the following procedure was followed: 5.5 ml of an aqueous solution of the Ru(III) complex with e 0.4 mg/ml (prepared by stirring at 37 C in bidistilled H20 for 5-10 minutes) were added to a 5. Previous HPLC studies and ultra,filtration experiments have demonstrated that no free complex is present after the stated time periods (Kratz et al. 1992 and 1994) . Thus, the protein/complex solutions were directly employed for the cell culture experiments. Apotransferrin or transferrin running as control were dissolved in the same buffer as above and then diluted with bidistilled H20 (150.0, 75.0, or 37.5 mg protein dissolved in 5.5 ml buffer to which 5.5 ml bidistilled. H20 were added).
Cell lines. For the in vitro experiments a human cancer cell line SW707 was used, which was derived from patients with colorectal cancer and was provided by the Tumor Bank of the Institute of Experimental Pathology, German Cancer Research Center (Heidelberg, FRG). SW707 is a cell line derived from welldifferentiated adenocarcinomas of the rectum with a modal chromosome number of 47. Microscopically, SW707 showed no microvesicular bodies. The cell line was routinely checked for their mucus production to exclude the possibility that fibroblasts had overgrown the carcinoma cells. Moreover, they were tested for
The manuscript giving details of the X-ray structure analysis is in preparation (Baker et al.) mycoplasma contamination and proved to be negative. The cell lines were grown as monolayer cultures in MEM medium (Gibco) supplemented with 10% heat-inactivated (57 C, 40 .min) fetal calf serum, streptomycin (100 tg/ml), penicillin (100 IU/ml) and L-glutamine (2 tmol/ml; all from Serva, Heidelberg, FRG). The cells were maintained in a humified atmosphere (5% CO2/95% air) at 37 C.
MTT test. Monolayer cell cultures were trypsinised and single-cell suspensions were obtained by repeated pipetting. The percentage of viability was determined by the trypan-blue exclusion test. A final concentration of approximately 2 x 104 cells/ml medium was prepared, and then 1.0 ml was added to each well of a 24-well culture plate. On the day following the plating; of cells, the test compounds were added at the respective concentrations. The MTT assay was performed after the cells had been incubated with the test substances for 3 consecutive days (days 2, 3 and 4). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, FRG) was dissolved in phosphate-buffered saline (Oxoid Ltd., Basingstoke, England) at 5 mg/ml and filtered through a 0.22-tm Millipore filter, after which 100 tl of this MTT solution was added to each well (0.1 ml/ml medium). After incubation of the plates with MTT for 1 h at 37 C, the medium was discarded and 500 tl acid-isopropanol (0.2 ml 0.04N HC1 in 10 ml isopropanol) was added to all wells to stop the enzyme reaction. Within 1 h of this addition the extinction of the colored formazon derivative dissolved in acid-isopropanol was determined on a flow Flow Multiscan MC plate reader at a wavelength of 540 nm (reference wavelength: 690 nm). At a given concentration, the MTT test was performend in 4 wells and the mean value calculated from these experiments is presented in Figures 1 and 2 . Standard deviations were below 15% and are not shown in the figure.
Results
The results of our cell culture experiments are shown in Figures 1A and B Figure 1A illustrates that the transferrin-bound forms of HInd[Rulnd2C14] exhibit a strong inhibitory effect at all of the concentrations tested when compared to the control and exceeds that ofthe free complex at the low dose of 25 tg/ml. By contrast, transferrin alone exhibits a strong stimulatory effect at high concentrations, and this result was to be expected considering that transferrin is an essential growth factor for cell culture.
The apotransferrin-bound form of HInd[RuInd2C14] is not as active as the transferrinbound form as can be seen in Figure lB . Also, the free complex exhibits a strongerinhibitory effect than the apotransferrin-bound forms. Nevertheless, the proteinbound form exhibits quite a strong inhibitory effect at the high concentration of 100 tg/ml compared to the control and exceeds that of pure apotransferrin, which also shows an inhibitory effect compared to the control. In contrast, the apotransfrrin-bound forms of th scond complex, HIm[RuIm2C14] xhibit a stronger inhibitory ffct than th fre complex, th protein-bound forms being about twic as activ as th fr complex ( Figure 2B ). Similar (Kratz t al., 1992) . This rsult suggests that apotransferdn or transfrdn could act as a natural carder of th drug to the tumor tissues owing to the high affinity between this mtal transport protein and the larg number oftransfrdn receptors on the sttrfac oftumor cells [Brock, 1985) . There is meanwhil a considerable amount of videnc available which demonstrates hat tumours in animals and man exhibit a vry high, "parasitic" uptake of iron(III) when they are fast growing. AulbCrt has reviewed th literature on this phenomenon (Aulbert, 1986) and together with his investigations demonstrated that turnout cells exhibit a high amount of transfrdn rcptors by which they sequester iron. Especially fast growing tumour cells show a much higher uptake ofiron-transferrin than the normal surrounding tissue of th affected organ. For these reasons, it is therefore tmpting to exploit th transferdn cycl as a "natural" rout for th sdectiv ddivry of cytostatic drugs to cancer calls. Transferrin is the iron-carrying protein in th serum of vertebrates. It is a -glycoprotein with a molecular wight of 80 000 and is present in human serum at a concentration of 2.5-3.5 mg/ml. The iron-free transfrdn is called apotransferrin and can bind two equivalents of F(III) in th N-and C-trminal lobes of the protein upon which the protein undergoes a conformational change. When encountering the cell surface, iron-bound transferrin binds to a specific cell surface receptor (transferrin receptor). The next step is intemalisation of the transferrin-receptor complex by endocytosis, followed by removal of iron from transferrin with the aid of intracellular chelates and involves fusion with endosomes, where the pH is lower (pH 5); finally the apotransferrin is returned to the extracellular medium. If the ruthenium complexes are being transported by transferrin or apotransferrin to the tumour cells, they have to be released again to exert their antitumour effect after the protein/complex-adduct has entered the tumour cell. The release should occur at low pHvalues (pH 5) with the aid of chelates. We have previously shown that both Ru(III) complexes can be released tom apotransferrin or transferrin at pH 4-5 in the presence of citric acid or ATP (Kratz et al., 1994) We are therefore planning animal experiments to strengthen our working hypothesis.
